New insights into the causes of heart failure

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 3, 2007, Pages 175-184

  Duhamel, Todd A ^a   Dhalla, Naranjan S ^a  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ALAGEBRIUM; ALISKIREN; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CYCLIC AMP; DIURETIC AGENT; ENALAPRIL; EPLERENONE; ETANERCEPT; ETOMOXIR; INFLIXIMAB; INOTROPIC AGENT; LEVOSIMENDAN; LOSARTAN; MATRIX METALLOPROTEINASE INHIBITOR; METOPROLOL; MILRINONE; NEUROHORMONE; OXIPURINOL; PG 116800; PG 530742; SPIRONOLACTONE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ORGANELLE; CHEMICAL ANALYSIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG TARGETING; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; MOLECULAR MECHANICS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION;

EID: 47249097583     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.12.001     Document Type: Review

References (73)

1. Rosamond W., et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Lloyd-Jones D.M., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002) 3068-3072
3. Guglin M., et al. Aldosterone antagonists: the most underutilized class of heart failure medications. Am. J. Cardiovasc. Drugs 7 (2007) 75-79
4. Cohn J.N., et al. Cardiac remodelling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35 (2000) 569-582
5. Guo X., et al. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the rennin-angiotensin system. Expert Rev. Cardiovasc. Ther. 3 (2005) 717-732
6. Sethi R., et al. Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy. J. Appl. Physiol. 102 (2007) 978-984
7. Poole-Wilson P.A., et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur. J. Heart Fail. 4 (2002) 321-329
8. Goldspink D.F., et al. Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways?. Exp. Physiol. 89 (2004) 407-416
9. Gallego M., et al. Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. Pharmacol. Res. 44 (2001) 311-315
10. Kawamura A., et al. Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure. Jpn. Circ. J. 65 (2001) 858-862
11. Cuffe M.S., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
12. Pfeffer M.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327 (1992) 669-677
13. van Gilst W.H., et al. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J. Am. Coll. Cardiol. 28 (1996) 114-121
14. The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327 (1992) 685-691
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325 (1991) 293-302
16. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316 (1987) 1429-1435
17. Dickstein K., and Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am. J. Cardiol. 83 (1999) 477-481
18. Pitt B., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study ELITE). Lancet 349 (1997) 747-752
19. Mitrovic V., et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am. Heart J. 145 (2003) E14
20. Kindermann M., et al. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin. Res.Cardiol. 96 (2007) 767-786
21. Azizi M., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 15 (2004) 3126-3133
22. Sepehrdad R., et al. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol. Rev. 15 (2007) 242-256
23. Seed A., et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur. J. Heart Fail. 9 (2007) 1120-1127
24. Oparil S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370 (2007) 221-229
25. Xu Y.J., et al. Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J. Cardiovasc. Pharmacol. Ther. 7 (2002) 109-115
26. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999) 709-717
27. Pitt B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
28. Wang J., et al. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J. Mol. Cell Cardiol. 34 (2002) 847-857
29. 2+ adenosine triphosphatase by phospholamban and sarcolipin: implication for cardiac hypertrophy and failure. Trends Cardiovasc. Med. 13 (2003) 152-157
30. Yano M., et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107 (2003) 477-484
31. Lehnart S.E. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr. Opin. Pharmacol. 7 (2007) 225-232
32. Arai M., et al. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ. Res. 72 (1993) 463-469
33. 2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92 (1995) 3220-3228
34. Suarez J., et al. In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H68-H75
35. Chen S.Y., and Tang W.H. Emerging drugs for acute and chronic heart failure: current and future developments. Expert. Opin. Emerg. Drugs 12 (2007) 75-95
36. Sorsa T., et al. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J. Mol. Cell Cardiol. 35 (2003) 1055-1061
37. Haikala H., et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol. 25 (1995) 794-801
38. Teramura S., and Yamakado T. Calcium sensitizers in chronic heart failure: inotropic interventions-reservation to preservation. Cardiologia 43 (1998) 375-385
39. Cleland J.G., et al. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur. J. Heart Fail. 8 (2006) 764-766
40. Lionetti V., et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc. Res. 66 (2005) 454-461
41. Schmidt-Schweda S., and Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. (Lond.) 99 (2000) 27-35
42. Nikolaidis L.A., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
43. Thrainsdottir I., et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res. 1 (2004) 40-43
44. Weber K.T., et al. Angiotensin II and extracellular matrix homeostasis. Int. J. Biochem. Cell Biol. 31 (1999) 395-403
45. Yarbrough W.M., et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 108 (2003) 1753-1759
46. Hudson M.P., et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. 48 (2006) 15-20
47. Little W.C., et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11 (2005) 191-195
48. Kass D.A., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
49. Sun M., et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115 (2007) 1398-1407
50. Sun M., et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110 (2004) 3221-3228
51. Torre-Amione G., et al. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 59 (2000) 745-751
52. McMurray J., and Pfeffer M.A. New therapeutic options in congestive heart failure. Part II. Circulation 105 (2002) 2223-2228
53. McMurray J., and Pfeffer M.A. New therapeutic options in congestive heart failure. Part I. Circulation 105 (2002) 2099-2106
54. Sia Y.T., et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 105 (2002) 2549-2555
55. Qin F., et al. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic. Biol. Med. 43 (2007) 271-281
56. Singh R.B., et al. Role of proteases in the pathophysiology of cardiac disease. Mol. Cell Biochem. 263 (2004) 241-256
57. Takahashi M., et al. Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. J. Cardiovasc. Pharmacol. 47 (2006) 413-421
58. Tappia P.S. Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can. J. Physiol. Pharmacol. 85 (2007) 25-41
59. Singal T., et al. Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem. Biophys. Res. Commun. 320 (2004) 1015-1019
60. Hill J.A., et al. Beyond diuretics: management of volume overload in acute heart failure syndromes. Am. J. Med. 119 (2006) S37-S44
61. Kalidindi S.R., et al. Drug insight: aldosterone-receptor antagonists in heart failure - the journey continues. Nat. Clin. Pract. Cardiovasc. Med. 4 (2007) 368-378
62. Motte S., et al. Endothelin receptor antagonists. Pharmacol. Ther. 110 (2006) 386-414
63. Drakos S.G., et al. Ventricular-assist devices for the treatment of chronic heart failure. Expert Rev. Cardiovasc. Ther. 5 (2007) 571-584
64. Pina I.L., et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 107 (2003) 1210-1225
65. Roveda F., et al. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J. Am. Coll. Cardiol. 42 (2003) 854-860
66. Whellan D.J., et al. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am. Heart J. 153 (2007) 201-211
67. 2+ handling protein expression in heart failure. Physiol. Genomics 29 (2007) 246-252
68. Follath F., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
69. Cleland J.G., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. 6 (2004) 501-508
70. 2+-sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J. Muscle Res. Cell Motil. 25 (2004) 219-224
71. Brixius K., et al. Different effect of the Ca(2+) sensitizers EMD-57033 and CGP 48506 on cross-bridge cycling in human myocardium. J. Pharmacol. Exp. Ther. 295 (2000) 1284-1290
72. Holubarsch C.J., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. (Lond). 113 (2007) 205-212
73. Freudenberger R.S., et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class. Expert. Opin. Investig. Drugs 13 (2004) 1509-1516